3.1.2b Peginterferon Alpha-2a (Pegasys)

Pegasys (peginterferon alpha-2a), Roche’s pegylated interferon, achieved a sustained virological response in 39% of patients, which is twice that achieved with the current treatment, interferon alpha-2a. The findings were presented at the 35th annual meeting of the European Association for the Study of the Liver (EASL), in Rotterdam, Netherlands, May 1-3, 2000. Pegasys is now approved in the US, Canada, and other countries.